Frontiers in Immunology (Aug 2022)
Detrimental NFKB1 missense variants affecting the Rel-homology domain of p105/p50
- Manfred Fliegauf,
- Manfred Fliegauf,
- Matias Kinnunen,
- Sara Posadas-Cantera,
- Nadezhda Camacho-Ordonez,
- Nadezhda Camacho-Ordonez,
- Hassan Abolhassani,
- Hassan Abolhassani,
- Laia Alsina,
- Laia Alsina,
- Faranaz Atschekzei,
- Faranaz Atschekzei,
- Delfien J. Bogaert,
- Delfien J. Bogaert,
- Siobhan O. Burns,
- Siobhan O. Burns,
- Joseph A. Church,
- Gregor Dückers,
- Alexandra F. Freeman,
- Lennart Hammarström,
- Leif Gunnar Hanitsch,
- Tessa Kerre,
- Robin Kobbe,
- Svetlana O. Sharapova,
- Kathrin Siepermann,
- Carsten Speckmann,
- Carsten Speckmann,
- Sophie Steiner,
- Nisha Verma,
- Jolan E. Walter,
- Jolan E. Walter,
- Jolan E. Walter,
- Emma Westermann-Clark,
- Emma Westermann-Clark,
- Sigune Goldacker,
- Sigune Goldacker,
- Klaus Warnatz,
- Klaus Warnatz,
- Markku Varjosalo,
- Markku Varjosalo,
- Markku Varjosalo,
- Bodo Grimbacher,
- Bodo Grimbacher,
- Bodo Grimbacher,
- Bodo Grimbacher
Affiliations
- Manfred Fliegauf
- Institute for Immunodeficiency (IFI), Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Manfred Fliegauf
- CIBSS – Centre for Integrative Biological Signalling Studies, Freiburg, Germany
- Matias Kinnunen
- Institute of Biotechnology, University of Helsinki, Helsinki, Finland
- Sara Posadas-Cantera
- Institute for Immunodeficiency (IFI), Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Nadezhda Camacho-Ordonez
- Institute for Immunodeficiency (IFI), Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Nadezhda Camacho-Ordonez
- Faculty of Biology, University of Freiburg, Freiburg, Germany
- Hassan Abolhassani
- Department of Biosciences and Nutrition, NEO, Karolinska Institutet, Huddinge, Sweden
- Hassan Abolhassani
- Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
- Laia Alsina
- Clinical Immunology and Primary Immunodeficiencies Unit, Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
- Laia Alsina
- Department of Surgery and Surgical Specializations, Facultat de Medicina i Ciències de la Salut, Barcelona, Spain
- Faranaz Atschekzei
- RESIST – Cluster of Excellence 2155 to Hanover Medical School , Satellite Center Freiburg, Freiburg, Germany
- Faranaz Atschekzei
- 0Department for Clinical Immunology and Rheumatology, Hannover Medical School, Hanover, Germany
- Delfien J. Bogaert
- 1Department of Pediatrics, Division of Pediatric Hemato-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium
- Delfien J. Bogaert
- 2Primary Immunodeficiency Research Lab, Center for Primary Immunodeficiency Ghent, Jeffrey Modell Diagnosis and Research Center, Ghent University Hospital, Ghent, Belgium
- Siobhan O. Burns
- 3Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom
- Siobhan O. Burns
- 4Institute of Immunity and Transplantation, University College London, London, United Kingdom
- Joseph A. Church
- 5Department of Pediatrics, Keck School of Medicine, University of Southern California and Children’s Hospital Los Angeles, Los Angeles, CA, United States
- Gregor Dückers
- 6HELIOS Children’s Hospital, Krefeld, Germany
- Alexandra F. Freeman
- 7Laboratory of Clinical Immunology and Microbiology, National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States
- Lennart Hammarström
- Department of Biosciences and Nutrition, NEO, Karolinska Institutet, Huddinge, Sweden
- Leif Gunnar Hanitsch
- 8Department of Medical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Tessa Kerre
- 9Department of Hematology, Ghent University Hospital, Ghent, Belgium
- Robin Kobbe
- 0Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Svetlana O. Sharapova
- 1Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus
- Kathrin Siepermann
- 6HELIOS Children’s Hospital, Krefeld, Germany
- Carsten Speckmann
- Institute for Immunodeficiency (IFI), Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Carsten Speckmann
- 2Center for Pediatrics and Adolescent Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Sophie Steiner
- 8Department of Medical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Nisha Verma
- 3Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom
- Jolan E. Walter
- 3Division of Allergy and Immunology, Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
- Jolan E. Walter
- 4Division of Allergy/Immunology, Department of Pediatrics Johns Hopkins All Children’s Hospital, St. Petersburg, FL, United States
- Jolan E. Walter
- 5Division of Allergy and Immunology, Massachusetts General Hospital for Children, Boston, MA, United States
- Emma Westermann-Clark
- 3Division of Allergy and Immunology, Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
- Emma Westermann-Clark
- 6Division of Allergy and Immunology, Department of Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
- Sigune Goldacker
- 7Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Sigune Goldacker
- 8Department of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Klaus Warnatz
- 7Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Klaus Warnatz
- 8Department of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Markku Varjosalo
- Institute of Biotechnology, University of Helsinki, Helsinki, Finland
- Markku Varjosalo
- 9Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
- Markku Varjosalo
- 0Proteomics Unit, University of Helsinki, Helsinki, Finland
- Bodo Grimbacher
- Institute for Immunodeficiency (IFI), Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Bodo Grimbacher
- CIBSS – Centre for Integrative Biological Signalling Studies, Freiburg, Germany
- Bodo Grimbacher
- RESIST – Cluster of Excellence 2155 to Hanover Medical School , Satellite Center Freiburg, Freiburg, Germany
- Bodo Grimbacher
- 1DZIF – German Center for Infection Research, Satellite Center Freiburg, Freiburg, Germany
- DOI
- https://doi.org/10.3389/fimmu.2022.965326
- Journal volume & issue
-
Vol. 13
Abstract
Most of the currently known heterozygous pathogenic NFKB1 (Nuclear factor kappa B subunit 1) variants comprise deleterious defects such as severe truncations, internal deletions, and frameshift variants. Collectively, these represent the most frequent monogenic cause of common variable immunodeficiency (CVID) identified so far. NFKB1 encodes the transcription factor precursor p105 which undergoes limited proteasomal processing of its C-terminal half to generate the mature NF-κB subunit p50. Whereas p105/p50 haploinsufficiency due to devastating genetic damages and protein loss is a well-known disease mechanism, the pathogenic significance of numerous NFKB1 missense variants still remains uncertain and/or unexplored, due to the unavailability of accurate test procedures to confirm causality. In this study we functionally characterized 47 distinct missense variants residing within the N-terminal domains, thus affecting both proteins, the p105 precursor and the processed p50. Following transient overexpression of EGFP-fused mutant p105 and p50 in HEK293T cells, we used fluorescence microscopy, Western blotting, electrophoretic mobility shift assays (EMSA), and reporter assays to analyze their effects on subcellular localization, protein stability and precursor processing, DNA binding, and on the RelA-dependent target promoter activation, respectively. We found nine missense variants to cause harmful damage with intensified protein decay, while two variants left protein stability unaffected but caused a loss of the DNA-binding activity. Seven of the analyzed single amino acid changes caused ambiguous protein defects and four variants were associated with only minor adverse effects. For 25 variants, test results were indistinguishable from those of the wildtype controls, hence, their pathogenic impact remained elusive. In summary, we show that pathogenic missense variants affecting the Rel-homology domain may cause protein-decaying defects, thus resembling the disease-mechanisms of p105/p50 haploinsufficiency or may cause DNA-binding deficiency. However, rare variants (with a population frequency of less than 0.01%) with minor abnormalities or with neutral tests should still be considered as potentially pathogenic, until suitable tests have approved them being benign.
Keywords
- primary immunodeficiency
- inborn errors of immunity (IEI)
- NFKB1
- common variable immunodeficiency (CVID)
- NF-kappaB signaling pathway